Association of serum level of 25 hydroxy-vitamin D with prognostic factors for breast cancer (original) (raw)
Related papers
International Journal of Hematology-Oncology and Stem Cell Research, 2016
In recent years, epidemiologic and laboratory studies have implied that vitamin D deficiency has a role in the pathogenesis of breast cancer. It has shown that vitamin D can prevent tumor progression induced by carcinogens and inhibit the carcinogenic effects of high fat diet on breast tissue and growth of tumor cells. This study aimed to evaluate serum 25-hydroxyvitamin D level and its role in relation to tumor characteristics and different stages of disease in women with breast cancer. This is a cross-sectional study on 200 patients with breast cancer at different stages of the disease. Information on age, menstrual status, BMI and tumor characteristics were recorded. Serum 25-hydroxy vitamin D concentrations were measured by radioimmunoassay (RIA). Mean and standard deviation were used to describe the data. Meanwhile, T-test and sum of squares test were used to analyze the data. P<0.05 was considered significant. Among 200 patients, 47 (23.5%) had severe vitamin D deficiency, ...
Role of serum levels of vitamin D in patients of breast Cancer
International Journal of Advanced Biochemistry Research, 2020
Background: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females. Breast cancer is a hormone dependent disease which occurs due to hyperestrogenic states. Aim and Objectives: To study the role of serum levels of vitamin D in patients of breast cancer and age matched control subjects along with comparison of lymph node positive and negative patients of breast cancer. Material and Methods: A total of 30 newly diagnosed patients of breast cancer with thirty age matched subjects as controls were included in the study. Serum was analysed for vitamin D levels by RIA Analyser SR300 method in both the groups. Results: The mean serum vitamin D level was significantly lower in cases as compared to controls (p <0.001). Vitamin D deficiency was found to be significantly higher in cases i.e. 80% than in controls i.e. 13.3% (p<0.0001). The mean serum vitamin D level was also comparable between lymph node positive and negative (p=0.934, p>0.05) cases. Conclusion: Vitamin D had anticarcinogenic effect due to their participation in regulating cell proliferation, differentiation and apoptosis in normal and malignant breast cells.
Evaluation of Vitamin D in Breast Cancer in a Tertiary Care Hospital
National Journal of Laboratory Medicine, 2017
Introduction: Vitamin D has been implicated to play a very important role in different types of cancers due to its pleotropic effects such as cell proliferation, cell differentiation, apoptosis etc. The implications of vitamin D deficiency are more evident in breast, prostate and colorectal cancer. Studies have revealed vitamin D supplementation reduces the risk of Breast cancer. Aim: The main objective of our study was to find out whether low serum 25-hydroxy vitamin D levels was associated with breast cancer. Materials and Methods: Study group included 25 diagnosed cases of breast cancer. Equal number of age and sex matched healthy persons were included in the control group. Serum 25-hydroxy vitamin D was estimated by electrochemiluminiscence immunoassay. Results: Mean vitamin D levels were low in breast cancer patients, when compared to controls (p-value < 0.05),which shows that low vitamin D levels are associated with increased risk of breast cancer. Conclusion: Our study sho...
Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer
Journal of Clinical Oncology, 2009
Purpose Vitamin D has been linked to breast cancer risk, but prognostic effects are unknown. Such effects are biologically plausible given the presence of vitamin D receptors in breast cancer cells, which act as nuclear transcription factors to regulate gene activity. Patients and Methods The study was conducted in a prospective inception cohort of 512 women with early breast cancer diagnosed 1989 to 1996. Vitamin D levels were measured in stored blood. Clinical, pathologic, and dietary data were accessed to examine prognostic effects of vitamin D. Results Mean age was 50.4 years, mean vitamin D was 58.1 ± 23.4 nmol/L. Vitamin D levels were deficient (< 50 nmol/L) in 37.5% of patients, insufficient (50 to 72 nmol/L) in 38.5% of patients, and sufficient (> 72 nmol/L) in 24.0% of patients. There was little variation in mean vitamin D levels between summer and winter months. Mean follow-up was 11.6 years; 116 women had distant recurrences, and 106 women died. Women with deficient...
Prognostic Impact of 25-Hydroxyvitamin D Levels in Egyptian Patients with Breast Cancer
Journal of Cancer Science & Therapy, 2017
Background: According to the literature, vitamin D (Vit D) deficiency is a risk factor for breast cancer developing with lack of information on its direct prognostic effects in breast cancer. Patients and methods: A total of 168 women with proven breast cancer diagnosed in Zagazig university hospitals-Egypt were enrolled in this study. Serum level of 25 (OH) Vit D was measured in stored blood just after diagnosis. Vit D levels were classified into three groups: deficient: <10 ng/ml; insufficient: 10 ng/ml to 30 ng/ml; and sufficient: >30 ng/ml. Clinical-pathological data and disease outcome were accessed to examine prognostic effect of vitamin D in breast cancer. Results: Median age was 51.5 (26-77) years, Metastasis was present in 13.1% of the cases. The median serum level of 25(OH) Vit D was 20 (5-98) ng/ml; it was deficient in 36.9% of patients, insufficient in 32.1% of patients, and sufficient in 31% of patients. Serum level of 25 (OH) VitD levels decreased significantly with increasing body mass index (BMI) (P=0.00), also the relations of 25 (OH) Vit D level with the number of positive lymph nodes, tumor size, tumor stage and KI 67 level were statistically significant (p= 0.01, p=0.011, p=0.002, p= 0.001 respectively). The level of 25 (OH) vitamin D was significantly low in metastatic patients (p=0.01). For those non-metastatic BC patients; there was no statistically significant difference in mean Disease-Free Survival (DFS) times across the 3 categories of serum Vitamin D (p=0.13), also for metastatic patients, serum vit D level didn't affect the median PFS (p=0.98). The mean OS of the 3 different categories of serum vit D (sufficient, insufficient and deficient) were 45.8 months, 39.7 months and 39 months respectively (p=0.047). Univariate analysis, showed that OS was significantly affected by age, BMI, grade, stage, molecular type and vit D levels (p=0.014, p=0.002, p=0.002, p<0.0001, and p=0.047 respectively), but in Multivariate analysis: age, BMI, stage, and vit D levels were the only independent factors significantly affect the OS (p=0.01, 0.001, p<0.0001 and p=0.022, respectively). Conclusion: There may be an association between serum 25 (OH) Vit D level and breast cancer prognosis.
A Study of Serum Vitamin D Levels in Newly Diagnosed Breast Cancer
IOSR Journals , 2019
Vitamin D is found to have anti neoplastic properties in Breast carcinoma and proven to have improved survival rate as evidenced by literature. Serum levels of Vitamin D in patients with breast carcinoma is found to have a significant impact on its incidence worldwide as evidenced by various laboratory and epidemiological studies.It is postulated that breast cells have Vitamin D receptor in their nuclei and polymorphism of genes for these Vitamin D receptor results in increased risk of breast cancer.
Serum 25-hydroxyvitamin D levels in early and advanced breast cancer
Journal of Clinical Pathology, 2006
Background: Laboratory and epidemiological studies have implicated vitamin D deficiency in the pathogenesis of breast cancer. 1,25-Dihydroxyvitamin D (1,25(OH) 2 D) promotes differentiation and apoptosis, and potently inhibits proliferation of malignant breast epithelial cells in culture. Serum levels of 1,25(OH) 2 D are higher in normal women than in patients with primary breast cancer. Aim: To clarify the role of vitamin D in breast cancer progression by comparing the levels of serum vitamin D in patients with early and in those with advanced breast cancer. Methods: Circulating levels of 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH) and calcium were measured prospectively in 279 Caucasian women with invasive breast cancer, 204 women with early-stage disease and 75 women with locally advanced or metastatic disease. Results: Patients with early-stage breast cancer had significantly higher circulating levels of 25(OH)D (p,0.005) and significantly lower PTH (p,0.001) levels than those with advanced disease. Calcium levels did not differ significantly (p = 0.74). Conclusion: Serum levels of 25(OH)D are significantly higher in patients with early-stage breast cancer than in those with locally advanced or metastatic disease.
Relation of Vitamin D Deficiency with Breast Cancer Staging in Patients from INMOL Cancer Hospital
2021
Introduction: Vitamin D deficiency can be critical and is reported to be as one of the factors for development and progression of breast carcinoma. Aims & Objectives: To measure and compare 25(OH)D (calcidiol) levels in healthy females and in breast carcinoma patients in four different stages. Place and duration of study: This cross sectional study and research was conducted in Shaikh Zayed Medical Complex in the Department of Biochemistry and Chemical Pathology from Jan 2018 to Jan 2019. The patients were selected from INMOL Cancer Hospital, Lahore. Material & Methods: The study was carried out on 39 healthy females (controls) and 156 newly diagnosed cases of carcinoma breast from stage I to IV, 39 patients of each stage. 25(OH)D was determined in blood samples of patients by ADVIA Centaur (XP) immunoassay system. Results: In this study the mean 25(OH)D level of healthy females with mean age of 41.7 ± 15.8 years, was 25.1 ± 5.5ng/ml. 25(OH) D level of breast cancer patients was fou...
Vitamin D Deficiency as a Risk Factor of Breast Cancer
Background: To determine the frequency of Vitamin D insufficiency in patients with breast cancer. Methods: In this comparative study diagnosed cases of carcinoma breast (n=50) were enrolled. Equal number were taken as control. Patients undergoing current dialysis treatment, elevated liver enzymes, primary hyperparathyroidism, hypercalcemia, hypercalciuria, or Paget's disease and already taking therapy to improve vitamin D levels were excluded. Vitamin D levels were measured by Enzyme Linked Immunosorbant Assay(ELISA).Chi square test was applied to compare the vitamin D deficiency in cases and controls. Odds ratio were calculated. Stratification was done for duration of disease (in months) age of patients, family history to control the effect modifier. Results: In our study, 64%(n=32) in cases and 100%(n=50) in controls were between 25-45 years of age while 36%(n=18) in cases group were between 46-65 years of age, Mean+SD was calculated as 40.60+10.02 and 32.08+4.12 respectively.Frequency of vitamin D deficiency was 92% in cases and 63% in controls. Conclusion: Fequency of Vitamin D insufficiency in patients with breast cancer was significantly higher as compared to the controls. Dietary vitamin D and casual sunlight exposure may be among the modifiable risk factors for breast cancer.
Vitamin D Deficiency as Etiological Factor for Breast Cancer
Pakistan Journal of Medical and Health Sciences
Aim: To determine the association between vitamin D deficiency and breast cancer. Material and methods: This study was conducted on 72 participants, 36 cases and 36 healthy controls were enrolled. Basic demographic information was recorded. Vitamins D deficiency was assessed between both groups. Serum Vitamin D level < 20 ng/ml was considered as vitamin D deficient. Results: Mean age in the cases was 34.64±9.14 years and 36.22±8.78 years in controls. Significant association was found between vitamins D deficiency and breast cancer. In cases there 28 (77.7%) patients with vitamin D deficient and in controls 15 (41.7%) patients. Conclusion: Vitamin D deficiency is a major risk factor for breast cancer.